Rani Therapeutics Holdings, Inc. (RANI)
0.6406
-0.04
(-5.79%)
USD |
NASDAQ |
Oct 16, 16:00
0.6392
0.00 (0.00%)
After-Hours: 20:00
Rani Therapeutics Holdings Enterprise Value : 30.78M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 30.78M |
| October 15, 2026 | 35.21M |
| October 14, 2026 | 34.11M |
| October 13, 2026 | 41.19M |
| October 12, 2026 | 43.18M |
| October 09, 2026 | 48.60M |
| October 08, 2026 | 47.81M |
| October 07, 2026 | 50.07M |
| October 06, 2026 | 51.95M |
| October 05, 2026 | 45.88M |
| October 02, 2026 | 49.92M |
| October 01, 2026 | 48.20M |
| September 30, 2026 | 47.70M |
| September 29, 2026 | 48.74M |
| September 28, 2026 | 46.01M |
| September 25, 2026 | 44.12M |
| September 24, 2026 | 42.97M |
| September 23, 2026 | 45.00M |
| September 22, 2026 | 46.22M |
| September 21, 2026 | 47.52M |
| September 18, 2026 | 55.68M |
| September 17, 2026 | 54.51M |
| September 16, 2026 | 43.76M |
| September 15, 2026 | 51.13M |
| September 14, 2026 | 52.74M |
| Date | Value |
|---|---|
| September 11, 2026 | 53.50M |
| September 10, 2026 | 51.18M |
| September 09, 2026 | 53.21M |
| September 08, 2026 | 56.86M |
| September 04, 2026 | 56.05M |
| September 03, 2026 | 54.58M |
| September 02, 2026 | 55.23M |
| September 01, 2026 | 55.96M |
| August 31, 2026 | 54.76M |
| August 28, 2026 | 53.21M |
| August 27, 2026 | 54.81M |
| August 26, 2026 | 53.37M |
| August 25, 2026 | 58.95M |
| August 24, 2026 | 57.60M |
| August 21, 2026 | 57.71M |
| August 20, 2026 | 54.45M |
| August 19, 2026 | 61.83M |
| August 18, 2026 | 51.57M |
| August 17, 2026 | 48.25M |
| August 14, 2026 | 48.27M |
| August 13, 2026 | 48.47M |
| August 12, 2026 | 49.02M |
| August 11, 2026 | 47.02M |
| August 10, 2026 | 46.11M |
| August 07, 2026 | 47.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 13.16M |
| CNBX Pharmaceuticals, Inc. | 1.379M |
| Arvinas, Inc. | -104.56M |
| Fulcrum Therapeutics, Inc. | -35.12M |
| Definium Therapeutics, Inc. | 3.266B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.421M |
| Revenue (Quarterly) | 1.708M |
| Total Expenses (Quarterly) | 9.099M |
| EPS Diluted (Quarterly) | -0.0395 |
| Gross Profit Margin (Quarterly) | 88.29% |
| Profit Margin (Quarterly) | -493.0% |
| Earnings Yield | -41.40% |
| Normalized Earnings Yield | -40.96 |